By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Lantheus Holdings 

331 Treble Cove Road

N. Billerica  Massachusetts  01862  U.S.A.
Phone: 1-800-362-2668 Fax: n/a


SEARCH JOBS

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada.

YEAR FOUNDED:

1956

LEADERSHIP:

CEO: Mary Anne Heino

CFO: Jack Crowley

CMO: Cesare Orlandi

JOBS:

Please click here for Lantheus Holdings.

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

All Products


Key Statistics


Email:
Ownership: Private

Web Site: Lantheus Holdings
Employees:
Symbol: 
 



Industry
Diagnostics






Company News
Lantheus Holdings Reports 2017 Second Quarter Financial Results; Exceeds Second Quarter And Raises Full-Year 2017 Guidance 8/2/2017 7:13:20 AM
Lantheus Holdings To Host Second Quarter 2017 Earnings Conference Call On August 1, 2017 At 4:30 P.M. Eastern Time 7/19/2017 7:39:17 AM
Lantheus Holdings Announces Public Secondary Offering By Selling Stockholders Of 3,000,000 Shares Of Common Stock 6/15/2017 8:20:26 AM
Lantheus Holdings Announces Public Secondary Offering By Selling Stockholders Of 3,000,000 Shares Of Common Stock 6/15/2017 7:13:44 AM
Lantheus Holdings Announces Public Secondary Offering By Selling Stockholders Of 3,000,000 Shares Of Common Stock 5/4/2017 7:00:34 AM
Lantheus Holdings Reports 2017 First Quarter Financial Results; Exceeds First Quarter And Raises Full-Year 2017 Guidance 5/3/2017 5:49:04 AM
Lantheus Holdings And GE Healthcare Announce The Signing Of A Definitive License Agreement For Worldwide Development And Commercialization Of Flurpiridaz F 18 4/25/2017 8:34:59 AM
Lantheus Holdings To Host First Quarter 2017 Earnings Conference Call On May 2, 2017 At 4:30 P.M. Eastern Time 4/19/2017 6:48:56 AM
Lantheus Holdings Announces Refinancing Of Its Debt Facility 3/31/2017 7:03:57 AM
Lantheus Holdings Announces Public Secondary Offering Of 3,000,000 Shares Of Common Stock By Selling Stockholders 3/14/2017 6:46:17 AM
12
//-->